TN2011000382A1 - Indole derivatives as crth2 receptor antagonists - Google Patents

Indole derivatives as crth2 receptor antagonists

Info

Publication number: TN2011000382A1
Authority: TN; Tunisia
Prior art keywords: receptor antagonists; indole derivatives; crth2 receptor; crth2; antagonists
Prior art date: 2009-02-24

Application number

TN2011000382A

Other languages

English (en)

Inventor

Carl Berthelette

Michael Boyd

John Colucci

Karine Villeneuve

Joey Methot

Original Assignee

Merck Sharp & Dohme

Merck Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-24

Filing date

2011-08-03

Publication date

2013-03-27

2011-08-03 Application filed by Merck Sharp & Dohme, Merck Canada Inc filed Critical Merck Sharp & Dohme

2013-03-27 Publication of TN2011000382A1 publication Critical patent/TN2011000382A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TN2011000382A 2009-02-24 2011-08-03 Indole derivatives as crth2 receptor antagonists TN2011000382A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15496809P	2009-02-24	2009-02-24
PCT/US2010/024713 WO2010099039A1 (fr)	2009-02-24	2010-02-19	Dérivés d'indole en tant qu'antagonistes du récepteur crth2

Publications (1)

Publication Number	Publication Date
TN2011000382A1 true TN2011000382A1 (en)	2013-03-27

Family

ID=42046150

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000382A TN2011000382A1 (en)	2009-02-24	2011-08-03	Indole derivatives as crth2 receptor antagonists

Country Status (36)

Country	Link
US (2)	US8394819B2 (fr)
EP (2)	EP2492267B1 (fr)
JP (1)	JP4989786B1 (fr)
KR (2)	KR101275980B1 (fr)
CN (1)	CN102333771B (fr)
AR (1)	AR075597A1 (fr)
AU (1)	AU2010218209B2 (fr)
BR (1)	BRPI1008906B1 (fr)
CA (1)	CA2752981C (fr)
CL (1)	CL2011002056A1 (fr)
CO (1)	CO6410295A2 (fr)
CR (1)	CR20110455A (fr)
DK (1)	DK2401269T3 (fr)
DO (1)	DOP2011000271A (fr)
EA (1)	EA021076B1 (fr)
EC (1)	ECSP11011288A (fr)
ES (2)	ES2529420T3 (fr)
HN (1)	HN2011002272A (fr)
HR (1)	HRP20140384T1 (fr)
IL (1)	IL214342A0 (fr)
MA (1)	MA33134B1 (fr)
MX (1)	MX2011008869A (fr)
MY (1)	MY152062A (fr)
NI (1)	NI201100162A (fr)
NZ (1)	NZ594767A (fr)
PE (1)	PE20120056A1 (fr)
PL (1)	PL2401269T3 (fr)
PT (1)	PT2401269E (fr)
RS (1)	RS53268B (fr)
SG (1)	SG173775A1 (fr)
SI (1)	SI2401269T1 (fr)
TN (1)	TN2011000382A1 (fr)
TW (2)	TWI444381B (fr)
UA (1)	UA105039C2 (fr)
WO (1)	WO2010099039A1 (fr)
ZA (1)	ZA201105767B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2737483A1 (fr) *	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Derives d'indole comme antagonistes du recepteur crth2
WO2010031184A1 (fr) *	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Dérivés d'azaindole comme antagonistes du récepteur crth2
KR20130133219A (ko)	2010-12-23	2013-12-06	머크 샤프 앤드 돔 코포레이션	Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린
WO2012087872A1 (fr)	2010-12-23	2012-06-28	Merck Sharp & Dohme Corp.	Quinoléines et aza-quinoléines en tant que modulateurs de l'activité du récepteur crth2
HUE028972T2 (en) *	2011-04-14	2017-01-30	Actelion Pharmaceuticals Ltd	7- (Heteroarylamino) -6,7,8,9-tetrahydropyrido [1,2-a] indole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
MX2013014900A (es)	2011-06-17	2014-02-17	Merck Sharp & Dohme	Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de la molecula receptora homologa quimioatrayente expresada en celulas t auxiliares de tipo 2.
WO2013043826A1 (fr)	2011-09-21	2013-03-28	Abbvie Inc.	Composés tricycliques utiles comme inhibiteurs de protéine kinase
CN103450218B (zh) *	2012-05-29	2015-12-23	山东亨利医药科技有限责任公司	作为crth2受体拮抗剂的吲哚类三并环衍生物
WO2014055311A1 (fr)	2012-10-01	2014-04-10	Merck Sharp & Dohme Corp.	Isoquinolines substituées utiles comme modulateurs du récepteur crth2
WO2014060596A1 (fr) *	2012-10-18	2014-04-24	Zach System S.P.A.	Procédé de préparation de dérivés d'indole
CN106103435B (zh)	2014-03-17	2018-11-16	爱杜西亚药品有限公司	氮杂吲哚乙酸衍生物及彼等作为前列腺素d2受体调节剂的用途
MX2016011900A (es)	2014-03-18	2016-12-05	Actelion Pharmaceuticals Ltd	Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
DK3277722T3 (da)	2015-04-02	2021-10-11	Intervet Int Bv	Antistoffer mod canin interleukin-4 receptor alpha
WO2017005764A1 (fr) *	2015-07-07	2017-01-12	Intervet International B.V.	Procédé de production d'intermédiaires tricyclocétones d'antagonistes de crth2
WO2017005766A1 (fr)	2015-07-07	2017-01-12	Intervet International B.V.	Procédé de production d'intermédiaires alcools tricycliques d'antagonistes de crth2
WO2017005759A1 (fr)	2015-07-07	2017-01-12	Intervet International B.V.	Procédé pour produire des dérivés d'azaindole
RU2018106032A (ru)	2015-07-23	2019-08-26	Мерк Шарп И Доум Корп.	Генетические маркеры, ассоциированные с ответом на антиагонисты рецептора crth2
PL3350179T3 (pl)	2015-09-15	2021-08-02	Idorsia Pharmaceuticals Ltd	Krystaliczne postacie
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913989QA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
WO2018111662A1 (fr)	2016-12-14	2018-06-21	Merck Sharp & Dohme Corp.	Marqueurs génétiques humains associés à une réponse à des traitements ciblant la toxine b de clostridium difficile
CN120514846A (zh)	2019-12-20	2025-08-22	英特维特国际股份有限公司	用于治疗特应性皮炎的双特异性犬源化抗体
AU2022331122A1 (en)	2021-08-20	2024-02-15	Intervet International B.V.	Homodimer fusion proteins for treating atopic dermatitis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
AU693143B2 (en)	1993-12-06	1998-06-25	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en)	1994-07-07	1996-04-23	Texas Biotechnology Corporation	Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU2964295A (en)	1994-07-11	1996-02-09	Athena Neurosciences, Inc.	Inhibitors of leukocyte adhesion
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en)	1994-12-24	1996-01-31	Zeneca Ltd	Chemical compounds
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
WO1996031206A2 (fr)	1995-04-07	1996-10-10	Warner-Lambert Company	Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
WO1996040781A1 (fr)	1995-06-07	1996-12-19	Tanabe Seiyaku Co., Ltd.	INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
AU6311996A (en)	1995-07-06	1997-02-05	Zeneca Limited	Peptide inhibitors of fibronectine
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
FR2827206B1 (fr)	2001-07-10	2004-04-02	Nature Bois Emballages	Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
US7534897B2 (en)	2002-05-16	2009-05-19	Shionogi & Co., Ltd.	Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
WO2004103970A1 (fr) *	2003-05-20	2004-12-02	Merck Frosst Canada Ltd.	Fluoro-methanesulfonyl- cycloalkanoindoles substitues et leur utilisation en tant qu'antagonistes de prostaglandine d2
DE602005006539D1 (de) *	2004-03-11	2008-06-19	Actelion Pharmaceuticals Ltd	Tetrahydropyridoindolderivate
TW200605885A (en)	2004-07-29	2006-02-16	Threshold Pharmaceuticals Inc	Multicyclic lonidamine analogs
GB0427381D0 (en) *	2004-12-14	2005-01-19	Novartis Ag	Organic compounds
PL1833791T3 (pl) *	2004-12-27	2011-12-30	Actelion Pharmaceuticals Ltd	Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
GB0505048D0 (en) *	2005-03-11	2005-04-20	Oxagen Ltd	Compounds with PGD antagonist activity
EP1915372B1 (fr) *	2005-08-12	2013-11-20	Merck Canada Inc.	Derives d'indole en tant qu'antagonistes du recepteur crth2
PT2051962E (pt) *	2006-08-07	2012-01-10	Actelion Pharmaceuticals Ltd	Derivados do ácido (3-amino-1,2,3,4-tetrahidro-9hcarbazol- 9-il)-acético
US20110112134A1 (en)	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
CA2737483A1 (fr)	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Derives d'indole comme antagonistes du recepteur crth2
WO2010031184A1 (fr) *	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Dérivés d'azaindole comme antagonistes du récepteur crth2
CA2737460C (fr)	2008-09-22	2016-12-20	Merck Frosst Canada Ltd.	Derives d'indole utilisables en tant qu'antagonistes du recepteur crth2
WO2010085820A2 (fr)	2009-01-26	2010-07-29	Amira Pharmaceuticals, Inc.	Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine

2010
- 2010-02-19 EP EP12168410.4A patent/EP2492267B1/fr active Active
- 2010-02-19 AU AU2010218209A patent/AU2010218209B2/en not_active Ceased
- 2010-02-19 CN CN201080010563.9A patent/CN102333771B/zh not_active Expired - Fee Related
- 2010-02-19 KR KR1020117019538A patent/KR101275980B1/ko not_active Expired - Fee Related
- 2010-02-19 HR HRP20140384AT patent/HRP20140384T1/hr unknown
- 2010-02-19 UA UAA201111313A patent/UA105039C2/uk unknown
- 2010-02-19 PT PT107050684T patent/PT2401269E/pt unknown
- 2010-02-19 MA MA34181A patent/MA33134B1/fr unknown
- 2010-02-19 US US12/708,924 patent/US8394819B2/en active Active
- 2010-02-19 RS RS20140213A patent/RS53268B/sr unknown
- 2010-02-19 PE PE2011001523A patent/PE20120056A1/es not_active Application Discontinuation
- 2010-02-19 SG SG2011059912A patent/SG173775A1/en unknown
- 2010-02-19 EA EA201171081A patent/EA021076B1/ru not_active IP Right Cessation
- 2010-02-19 JP JP2011550331A patent/JP4989786B1/ja not_active Expired - Fee Related
- 2010-02-19 KR KR1020137005315A patent/KR101276530B1/ko not_active Expired - Fee Related
- 2010-02-19 EP EP10705068.4A patent/EP2401269B1/fr active Active
- 2010-02-19 ES ES12168410.4T patent/ES2529420T3/es active Active
- 2010-02-19 CA CA2752981A patent/CA2752981C/fr not_active Expired - Fee Related
- 2010-02-19 WO PCT/US2010/024713 patent/WO2010099039A1/fr not_active Ceased
- 2010-02-19 MX MX2011008869A patent/MX2011008869A/es active IP Right Grant
- 2010-02-19 SI SI201030527T patent/SI2401269T1/sl unknown
- 2010-02-19 PL PL10705068T patent/PL2401269T3/pl unknown
- 2010-02-19 DK DK10705068.4T patent/DK2401269T3/da active
- 2010-02-19 ES ES10705068.4T patent/ES2450594T3/es active Active
- 2010-02-19 BR BRPI1008906-3A patent/BRPI1008906B1/pt not_active IP Right Cessation
- 2010-02-19 NZ NZ594767A patent/NZ594767A/xx not_active IP Right Cessation
- 2010-02-19 MY MYPI2011003785 patent/MY152062A/en unknown
- 2010-02-23 TW TW102128348A patent/TWI444381B/zh not_active IP Right Cessation
- 2010-02-23 TW TW099105206A patent/TWI454474B/zh not_active IP Right Cessation
- 2010-02-24 AR ARP100100535A patent/AR075597A1/es not_active Application Discontinuation
2011
- 2011-07-28 IL IL214342A patent/IL214342A0/en unknown
- 2011-08-03 TN TN2011000382A patent/TN2011000382A1/fr unknown
- 2011-08-05 ZA ZA2011/05767A patent/ZA201105767B/en unknown
- 2011-08-23 CL CL2011002056A patent/CL2011002056A1/es unknown
- 2011-08-23 NI NI201100162A patent/NI201100162A/es unknown
- 2011-08-23 HN HN2011002272A patent/HN2011002272A/es unknown
- 2011-08-24 DO DO2011000271A patent/DOP2011000271A/es unknown
- 2011-08-24 EC EC2011011288A patent/ECSP11011288A/es unknown
- 2011-08-24 CR CR20110455A patent/CR20110455A/es unknown
- 2011-08-30 CO CO11111105A patent/CO6410295A2/es not_active Application Discontinuation
2013
- 2013-02-07 US US13/762,050 patent/US9023864B2/en active Active

Also Published As

Publication number	Publication date
CO6410295A2 (es)	2012-03-30
KR101275980B1 (ko)	2013-06-17
BRPI1008906B1 (pt)	2019-10-15
IL214342A0 (en)	2011-09-27
PL2401269T3 (pl)	2014-07-31
PT2401269E (pt)	2014-03-11
KR101276530B1 (ko)	2013-06-18
US20100234415A1 (en)	2010-09-16
HN2011002272A (es)	2014-02-24
CR20110455A (es)	2012-01-10
EP2401269A1 (fr)	2012-01-04
RS53268B (sr)	2014-08-29
UA105039C2 (uk)	2014-04-10
SG173775A1 (en)	2011-09-29
MX2011008869A (es)	2011-12-16
HRP20140384T1 (en)	2014-05-23
US20130150398A1 (en)	2013-06-13
US8394819B2 (en)	2013-03-12
ES2450594T3 (es)	2014-03-25
ECSP11011288A (es)	2011-10-31
US9023864B2 (en)	2015-05-05
TWI444381B (zh)	2014-07-11
JP2012517484A (ja)	2012-08-02
EP2492267B1 (fr)	2014-11-26
EP2401269B1 (fr)	2014-01-29
CN102333771B (zh)	2014-03-19
CN102333771A (zh)	2012-01-25
BRPI1008906A2 (pt)	2016-03-15
NZ594767A (en)	2013-05-31
TWI454474B (zh)	2014-10-01
EP2492267A1 (fr)	2012-08-29
ES2529420T3 (es)	2015-02-19
DK2401269T3 (da)	2014-04-28
AU2010218209A1 (en)	2011-08-25
ZA201105767B (en)	2012-04-25
TW201402573A (zh)	2014-01-16
JP4989786B1 (ja)	2012-08-01
EA021076B1 (ru)	2015-03-31
KR20110107395A (ko)	2011-09-30
AR075597A1 (es)	2011-04-20
CA2752981C (fr)	2013-11-12
MA33134B1 (fr)	2012-03-01
HK1160465A1 (en)	2012-08-17
EA201171081A1 (ru)	2012-02-28
MY152062A (en)	2014-08-15
KR20130028156A (ko)	2013-03-18
SI2401269T1 (sl)	2014-04-30
CL2011002056A1 (es)	2012-04-09
CA2752981A1 (fr)	2010-09-02
PE20120056A1 (es)	2012-02-05
DOP2011000271A (es)	2011-10-15
NI201100162A (es)	2012-02-01
WO2010099039A1 (fr)	2010-09-02
TW201035096A (en)	2010-10-01
AU2010218209B2 (en)	2012-12-13

Publication	Publication Date	Title
TN2011000382A1 (en)	2013-03-27	Indole derivatives as crth2 receptor antagonists
WO2010031184A8 (fr)	2010-06-17	Dérivés d'azaindole comme antagonistes du récepteur crth2
IN2012DN02735A (fr)	2015-09-11
IN2012DN02702A (fr)	2015-09-04
ATE502921T1 (de)	2011-04-15	Substituierte indole
MY153915A (en)	2015-04-15	Organic compounds
MY163055A (en)	2017-08-15	Polycyclic antagonists of lysophosphatidic acid receptors
MY181898A (en)	2021-01-12	Heterocyclic compounds and uses thereof
TNSN07325A1 (en)	2008-12-31	Pgd2 receptor antagonists for the treatment of inflammatory diseases
UA96785C2 (uk)	2011-12-12	Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
PH12012500674A1 (en)	2016-06-15	Heterocyclic compounds useful as pdk1 inhibitors
MY147649A (en)	2012-12-31	Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
MA33937B1 (fr)	2013-01-02	Composes pyrazole comme antagonistes du recepteur crth2
GB2460597A (en)	2009-12-09	N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
MX2008013196A (es)	2008-10-22	5-amido-2-carboxiamida-indoles.
MX2010006206A (es)	2011-03-04	Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2011013032A (es)	2012-02-08	Inhibidores de fosfatidilinositol 3-cinasa.
MX2009010376A (es)	2010-01-20	Derivados de quinolina como ligandos del receptor crth2.
NZ594186A (en)	2012-12-21	Indole derivatives as anticancer agents
MY152030A (en)	2014-08-15	Novel herbicides
MY185134A (en)	2021-04-30	6-substituted phenoxychroman carboxylic acis derivatives
IN2012DN03844A (fr)	2015-08-28
MY157425A (en)	2016-06-15	Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
MX2011008645A (es)	2011-09-30	Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX2011008126A (es)	2011-08-17	Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.